https://www.selleckchem.com/pr....oducts/CP-690550.htm
Further, PCI-24781 decreased tumor burden in a PEPG GBM mouse model. Notably, TMZ + PCI increased survival in orthotopic murine models compared to TMZ + vorinostat, a pan-HDAC inhibitor that proved unsuccessful in clinical trials. PCI-24781 is a novel GBM-signature specific HDAC inhibitor that works synergistically with TMZ to enhance TMZ efficacy and improve GBM survival. These promising MGMT-agnostic results warrant clinical evaluation. PCI-24781 is a novel GBM-signature specific HDAC inhibitor that works synergistically with TMZ to
Like
Comment
Share
